XiaoMi-AI文件搜索系统
World File Search Systemmeaningful
CADTH Reimbursement Recommendation
One double-blind, phase 2/3, randomized controlled trial (RCT) (N-MOmentum, N = 230) in patients with NMOSD demonstrated that, among AQP4 seropositive patients (N = 213) treatment with inebilizumab likely results in a clinically meaningful increase in time to first relapse and a reduction in the proportion of patients with worsening in Expanded Disability Status Scale (EDSS) compared to treatment with placebo after 197 days of treatment. Among AQP4 seropositive patients, the hazard ratio (HR) for time to first Adjudication Committee (AC)–determined NMOSD attack was 0.28 (95% confidence interval [CI]: 0.12 to 0.42, P < 0.0001) and at day 197, 87.6% of patients in the inebilizumab group were attack-free compared to 56.6% in the placebo group, which equated to a 77.3% reduction in the risk of AC-determined NMOSD attack. The CADTH review of the sponsor's submitted indirect treatment comparisons concluded that inebilizumab did not offer a benefit relative to eculizumab, and that imprecision in the estimated HR prevented a definitive conclusion from being reached in the comparison with satralizumab.
与 AWS 使用相关的法律问题.pdf
4参见，例如：Daniele Amoroso和Guglielmo Tamburrini，“使人类对武器的控制“有意义”（2019年）ICRAC报告； Vincent Boulanin等人，“武器系统中自治的限制：确定人类控制的实际要素”（2020）SIPRI报告；丽贝卡·克鲁特（Rebecca Crootof），“有意义的人类控制”（2016）30 Temple International and Comparative Law Journal 53; Merel Ekelhof，“自动武器：操作有意义的人类控制”（2018）ICRC博客；迈克尔·霍洛维茨（Michael C Horowitz）和保罗·沙尔（Paul Scharre），“武器系统中有意义的人类控制：底漆”（2015）CNAS工作文件； Thilo Marauhn，“有意义的人类控制 - 国际法政治”中的《沃尔夫·海因特·冯·海内格》，罗伯特·弗劳（Robert Frau）和塔西洛·辛格（Robert Frau）和塔西洛·辛格（Tassilo Singer），《战争的非人性化：新武器技术的法律意义》（Springer 2018），2018年，207-218，207-218。
创新准备级
创新准备级别的评估标准是UOFL创新和技术转移用于创新披露的使用，请注意，以下任何类别上的“红色”状态表明，创新尚未准备好向知识产权保护和商业化迈进。“黄色”状态意味着存在问题或赤字，但是有一个很好的计划来解决/克服它。“绿色”状态表示没有问题或问题。为了接收“ GO”，大多数类别应该具有绿色状态。任何红色状态都是不向技术前进的理由。ULRF ID#: Innovation Title: Evaluation Reason (Initial Disclosure or Patenting Investment Decision): Evaluator Name: _____________________________________________________________________________________ Invention Readiness Description is complete, thorough, clear, meaningful, innovation reduced to practice vs. merely a concept, a clear product or service can be described Status notes: Red , yellow or green and written justification Enforceability of IP Patentability is可以写出明确，有效的索赔，可强制执行的主题（可以看到侵权，而不是在制造过程中隐藏它），请注意是否可用或替代IP策略（TM，©，生物材料）？状态注意：红色，黄色或绿色和书面辩护
预告片SpaceTech行业框架
● Development and deployment of Earth observation satellites and other space-based platforms, such as the International Space Station, to gather data and imagery of the Earth from space.● Use of remote sensing technologies, including radar and optical sensors, to capture high-resolution images and data on various aspects of the Earth, such as weather patterns, land use, and natural resources.● Data analysis and interpretation using advanced algorithms and machine learning techniques to extract meaningful insights and patterns from the vast amounts of data collected from space.● Provision of data products and services to a range of industries, including agriculture, forestry, energy, and environmental management, to support decision-making and improve operational efficiency.● Collaboration with government agencies and research institutions to develop and implement space-based observation and monitoring programs to address global challenges, such as climate change, natural disasters, and ecosystem management.● Development of new technologies and solutions to improve the accuracy and precision of Earth observation and remote sensing data, such as new sensors and platforms, and advanced signal processing and data analysis techniques.● Promotion of public awareness and education on the value of space-based observation and monitoring, and the potential for these technologies to address critical global challenges and support sustainable development.
Cadth报销建议
一阶段III，双盲，安慰剂对照试验（敏捷; n = 146）表明，ivosidenib与氮杂丁丁（ivosidenib + Azacitidine）结合使用，从而增加了与IDH1 R132突变的新诊断为AML的成年患者，从而使成人患者与非强化化学相关化，从而增加了临床益处。The AGILE trial demonstrated that ivosidenib + azacitidine, when compared with placebo + azacitidine, resulted in statistically significant and clinically meaningful improvements in event-free survival (EFS) (hazard ratio [HR] = 0.33; 95% confidence interval [CI]: 0.16 to 0.69; P = 0.0011) and overall survival (OS) (HR = 0.44; 95％CI：0.27至0.73; p = 0.0005）在中间的随访时间。2年中位随访时间为28.6个月的OS率为53.1％（95％CI：|||| || |||||）和17.4％（95％CI：||| || || ||||）分别为ivosidenib + Azacitidine和chartbo + Azacitidine和Azacitidine群。PERC认为，与安慰剂 +阿扎西替丁相比，伊沃西二尼 +偶氮丁胺的安全性是可管理的，治疗伴随不良事件（TEAES）和3级茶水的发生率相似。PERC讨论了通过Ivosidenib治疗的QT延长和分化综合征的风险，并指出需要进行足够的监测和潜在剂量调整。
公共行政部门使用人工智能的问责制
4 当雇主强制使用系统时，这既属于“分布式责任”类别，也属于“外部诱导的自动化接受”类别。这里讨论的案例是两者的一个例子，由于是外部诱导的例子，它必然是有意义的控制的失败。但这不是由于分布式责任而导致的有效控制的失败，因为责任可以以平等的方式分配。在这种情况下，技术的使用不一定是外部诱导的，有意义的控制可能会得到保留。尽管如此，如果问题持续存在，分布式责任使得很难确定谁应该承担责任，正如我们将在第 3 节中看到的那样。
保诚标准APS 330公共披露
38。模板和表中提供的信息必须对用户有意义。在BCBS标准中的披露要求是明确确定需要对ADI进行评估的。准备这些单独的表格和模板时，ADI必须考虑披露要求的广泛应用。如果ADI认为在模板或表中要求的信息对用户没有意义，例如，因为暴露和风险加权资产（RWA）金额被认为是非物质的，它可能会选择不披露部分或所有请求的信息。在这种情况下，ADI必须在叙事评论中解释为什么它认为此类信息对用户没有意义。它还必须描述投资组合
Pomodoro技术对学生Mendelian遗传学的影响
最近，关于在不同专业领域使用基于大脑的教学策略来提高生产率的各种主张，从与业务相关的工作到教育领域（Wang等，2010； Shammas，2019）。The course "Learning how to Learn" by McMaster University and the University of California defined brain-based teaching as the strategy that engages the focused, pre-frontal cortex brain area and diffused mode, the rest of the cerebrum simultaneously resulting in stronger neural connections, more meaningful learning experiences and enhanced memory storage in an educational context (Jensen, 2005; Sousa, 2016) .Saleh＆Mazlan（2019）发现，神经认知学习刺激了参加物理课的学生的概念理解和掌握。此外，它还决心在科学课程中影响知识保留（Ozden＆Gultekin，2008）。Sani等人的研究。 （2019）表明，与讲座策略相比，诸如脑健身房和思维映射等策略显着增加了学生对学生的认知领域（记住，理解和分析）；有利于神经认知策略的这种显着差异已通过多项研究确定（Uzezi＆Jonah，2017； Sani等，2019）。Sani等人的研究。（2019）表明，与讲座策略相比，诸如脑健身房和思维映射等策略显着增加了学生对学生的认知领域（记住，理解和分析）；有利于神经认知策略的这种显着差异已通过多项研究确定（Uzezi＆Jonah，2017； Sani等，2019）。
Cadth报销建议
1阶段III，多中心，开放标签，随机对照试验（Destiny-breast04; n = 557）的证据表明，曲妥珠单抗Deruxtecan的治疗可改善成年患者的生存率，使成人患者的生存率提高在完成辅助化疗后或在6个月内发生了疾病复发。HR+ BC的命运 - 胸04试验中的患者至少接受了一项ET，并且不再考虑进一步的ET。The DESTINY-Breast04 trial showed that, when compared to physician's choice chemotherapy (TPC), treatment with trastuzumab deruxtecan was associated with a statistically significant and clinically meaningful improvement in OS (full analysis set median OS [95% CI] 23.4 months [20.0 to 24.8] vs 16.8 months [14.5 to 20.0]; P value 0.0010) and in PFS (full分析设置中位数PF [95％CI] 9.9个月[9.0至11.3] vs 5.1个月[4.2至6.8]；与接受TPC（16.3％）的患者相比，接受曲妥珠单抗Deruxtecan（52.3％）的患者的客观缓解率（ORR）较高，而在TPC组中，TPC手臂中有1.1％的反应是tpc的1.1％，与该人群中的1.1％相比，曲妥珠单抗Deruxtecan ARM中的反应的3.5％是罕见的反应。曲妥珠单抗Deruxtecan与可管理的毒性概况有关。